Skip to content

Supernus Pharmaceuticals SUPN Other Non-Current Assets

Other Non-Current Assets at other companies

Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$1.06M+401%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$3.93M+170%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$54.88M+20.8%
AbbVie logo
AbbVieABBV
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.58B+62.8%
Enterprise value$2.44B+62.3%
P/S3.3×+0.9×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Supernus Pharmaceuticals's other non-current assets?
Supernus Pharmaceuticals (SUPN) reported other non-current assets of $56.45M in Q1 2026.
How has Supernus Pharmaceuticals's other non-current assets changed year-over-year?
Supernus Pharmaceuticals's other non-current assets increased by 93.2% year-over-year, from $29.22M to $56.45M.
What is the long-term trend for Supernus Pharmaceuticals's other non-current assets?
Over 5 years (2020 to 2025), Supernus Pharmaceuticals's other non-current assets has grown at a 8.1% compound annual growth rate (CAGR), from $43.25M to $63.8M.
What does other non-current assets mean?
This category captures long-term assets that do not fit into standard classifications like property, plant, equipment, or intangible assets. It may include long-term deposits, deferred tax assets, or other miscellaneous non-current investments. It represents the residual value of long-term resources held by the company.